Research Articles | Page 2 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria Jun 2024 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria Jun 2024 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply Jun 2024 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria Mar 2024 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Jan 2020 The New England Journal of Medicine Myelodysplastic Syndromes (MDS)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Mar 2021 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Sep 2024 The Lancet Haematology Myelodysplastic Syndromes (MDS)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial Jun 2019 The Lancet Haematology Myelodysplastic Syndromes (MDS)